News
Regulatory affairsRegulatory Round-up - February 2026
CGT Catapult awarded two Princess Royal Training Awards for its skills and training programmesNew evaluation model finds widespread adoption of cell and gene therapies may unlock billions for the UK economyUnderstanding life with Beta ThalassemiaCGT Catapult and Autolomous showcase benefits of digital technologies in advanced therapy manufacturingRegulatory Round-up - September 2025R&D project spotlight: Deciphering rAAV production dynamics in HEK293 clones through multi-omics profilingCGT Catapult supporting VascVersa to develop pre-treatment test to ensure efficacy of cell therapy that regenerates blood vesselsThe case for collaboration: Why going it alone is no longer an option in advanced therapy developmentRegulatory Round-up - August 2025R&D project spotlight: Developing a smart bioprocessing platform integrating real-time process monitoring and advanced process control for autologous cell therapyRegulatory Round-up - July 2025MHRA introduces regulations that allow decentralised manufacturing of therapies